This study delved into the rare world of mixed neuroendocrine-non-neuroendocrine neoplasms in colorectal cancer and their more aggressive counterpart, neuroendocrine carcinomas. They found that adjuvant chemotherapy significantly improved survival for patients with stage III mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas. The median survival for these groups was similar, emphasizing the importance of adjuvant treatment in enhancing survival rates. The study highlights the need for further research to identify specific patient subsets that would benefit the most from adjuvant therapy.
Journal Article by Suraju MO, Freischlag K (…) Hassan I et 7 al. in BMC Surg
Copyright © 2023 Elsevier Inc. All rights reserved.